LRRC8A and neoplasm: To evaluate the in vivo impact of ATP release via VRACs on tumor progression, LRRC8A knockdown (shA1) and control MDA-MB231 cells were subcutaneously injected into the left and right sides of the lower back of nude mice, respectively.